SCHEMBL2232497

SCHEMBL2232497

COC(=O)NN(C(=O)Oc1ccc(C)cc1)c1ccccc1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
PTGES O14684 1/20 0.40
RAB9A P51151 1/20 0.40
NPC1 O15118 1/20 0.40
LIPE Q05469 1/20 0.40
STAT3 P40763 1/20 0.40
GAA P10253 1/20 0.39
HPGD P15428 2/20 0.39
XBP1 P17861 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TP53 P04637 1/20 0.37
ATM Q13315 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2235392 0.91 POLB (0.41) MAPTSMN1; SMN2MEN1KMT2APTGES
SCHEMBL2236294 0.89 ATM (0.47) MAPTSMN1; SMN2MEN1KMT2ANPC1
SCHEMBL2232860 0.86 ATM (0.44) MAPTSMN1; SMN2KMT2ALIPESTAT3
SCHEMBL2233414 0.85 LIPE (0.53) MAPTMEN1KMT2ARAB9ALIPE
SCHEMBL2233290 0.84 ALDH1A1 (0.50) MAPTSMN1; SMN2MEN1KMT2AGAA
SCHEMBL2237995 0.82 HPGD (0.41) MAPTSMN1; SMN2MEN1KMT2APTGES
SCHEMBL2235417 0.82 KMT2A (0.43) MAPTSMN1; SMN2MEN1KMT2ANPC1
SCHEMBL2234563 0.79 KDM4E (0.43) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL2237040 0.79 PTGES (0.48) MAPTSMN1; SMN2MEN1KMT2APTGES
SCHEMBL2236089 0.78 ALDH1A1 (0.43) MAPTMEN1KMT2APTGESHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299264-B2 Method for producing oxadiazolinone compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-30 US disclosed
US-20110207936-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-25 US disclosed
EP-2357167-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF Sumitomo Chemical Company, Limited (JP) 2011-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207936-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF AHR, CYP1B1, AR MAPT 3838/4885SMN1; SMN2 3381/4885MEN1 2516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.